APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Transmucosal Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral Transmucosal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchOral Transmucosal Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Transmucosal Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Oral Transmucosal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Transmucosal Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Transmucosal Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Oral Transmucosal Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral Transmucosal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Transmucosal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Transmucosal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral Transmucosal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Transmucosal Drugs include Access Pharmaceutical Inc., Aquestive Therapeutics, Inc., Bristol-Myers Squibb Company, C.L Pharm, Cure Pharmaceutical, Eisai Co., Ltd., IntelGenx Corp., LTS Lohmann Therapie-Systeme AG and NAL Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Transmucosal Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Transmucosal Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Transmucosal Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Transmucosal Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Transmucosal Drugs Segment by Company

Access Pharmaceutical Inc.

Aquestive Therapeutics, Inc.

Bristol-Myers Squibb Company

C.L Pharm

Cure Pharmaceutical

Eisai Co., Ltd.

IntelGenx Corp.

LTS Lohmann Therapie-Systeme AG

NAL Pharma

Otsuka Pharmaceutical Co., Ltd.

Soligenix

Viatris

ZIM Laboratories Limited

GlaxoSmithKline plc

Teva Pharmaceutical Industries Ltd.

Oral Transmucosal Drugs Segment by Type

Liquid Spray

Tablets

Gels

Films

Others

Oral Transmucosal Drugs Segment by Application

Cardiovascular Disorders

Diabetes

Acute Pain Managements

Others

Oral Transmucosal Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Transmucosal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Transmucosal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Transmucosal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Transmucosal Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Transmucosal Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral Transmucosal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral Transmucosal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral Transmucosal Drugs Industry Trends Table 2. Oral Transmucosal Drugs Industry Drivers Table 3. Oral Transmucosal Drugs Industry Opportunities and Challenges Table 4. Oral Transmucosal Drugs Industry Restraints Table 5. Global Oral Transmucosal Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral Transmucosal Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral Transmucosal Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Oral Transmucosal Drugs Sales Market Share by Manufacturers Table 9. Global Oral Transmucosal Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Oral Transmucosal Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral Transmucosal Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral Transmucosal Drugs Manufacturers, Product Type & Application Table 13. Global Oral Transmucosal Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Transmucosal Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Liquid Spray Table 17. Major Manufacturers of Tablets Table 18. Major Manufacturers of Gels Table 19. Major Manufacturers of Films Table 20. Major Manufacturers of Others Table 21. Global Oral Transmucosal Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Oral Transmucosal Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global Oral Transmucosal Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global Oral Transmucosal Drugs Sales Market Share by Type (2021-2026) Table 25. Global Oral Transmucosal Drugs Sales Market Share by Type (2027-2032) Table 26. Global Oral Transmucosal Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Oral Transmucosal Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global Oral Transmucosal Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global Oral Transmucosal Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Oral Transmucosal Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Cardiovascular Disorders Table 32. Major Manufacturers of Diabetes Table 33. Major Manufacturers of Acute Pain Managements Table 34. Major Manufacturers of Others Table 35. Global Oral Transmucosal Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Oral Transmucosal Drugs Sales by Application (2021-2026) & (K Units) Table 37. Global Oral Transmucosal Drugs Sales by Application (2027-2032) & (K Units) Table 38. Global Oral Transmucosal Drugs Sales Market Share by Application (2021-2026) Table 39. Global Oral Transmucosal Drugs Sales Market Share by Application (2027-2032) Table 40. Global Oral Transmucosal Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Oral Transmucosal Drugs Revenue by Application (2021-2026) & (K Units) Table 42. Global Oral Transmucosal Drugs Revenue by Application (2027-2032) & (K Units) Table 43. Global Oral Transmucosal Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Oral Transmucosal Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Oral Transmucosal Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Oral Transmucosal Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global Oral Transmucosal Drugs Sales Market Share by Region (2021-2026) Table 48. Global Oral Transmucosal Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Oral Transmucosal Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 52. North America Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 53. Europe Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 55. Europe Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Oral Transmucosal Drugs Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Oral Transmucosal Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global Oral Transmucosal Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Oral Transmucosal Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Oral Transmucosal Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Oral Transmucosal Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Oral Transmucosal Drugs Revenue Market Share by Region (2027-2032) Table 67. Access Pharmaceutical Inc. Company Information Table 68. Access Pharmaceutical Inc. Business Overview Table 69. Access Pharmaceutical Inc. Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Access Pharmaceutical Inc. Oral Transmucosal Drugs Product Portfolio Table 71. Access Pharmaceutical Inc. Recent Development Table 72. Aquestive Therapeutics, Inc. Company Information Table 73. Aquestive Therapeutics, Inc. Business Overview Table 74. Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Product Portfolio Table 76. Aquestive Therapeutics, Inc. Recent Development Table 77. Bristol-Myers Squibb Company Company Information Table 78. Bristol-Myers Squibb Company Business Overview Table 79. Bristol-Myers Squibb Company Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Bristol-Myers Squibb Company Oral Transmucosal Drugs Product Portfolio Table 81. Bristol-Myers Squibb Company Recent Development Table 82. C.L Pharm Company Information Table 83. C.L Pharm Business Overview Table 84. C.L Pharm Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. C.L Pharm Oral Transmucosal Drugs Product Portfolio Table 86. C.L Pharm Recent Development Table 87. Cure Pharmaceutical Company Information Table 88. Cure Pharmaceutical Business Overview Table 89. Cure Pharmaceutical Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Cure Pharmaceutical Oral Transmucosal Drugs Product Portfolio Table 91. Cure Pharmaceutical Recent Development Table 92. Eisai Co., Ltd. Company Information Table 93. Eisai Co., Ltd. Business Overview Table 94. Eisai Co., Ltd. Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Eisai Co., Ltd. Oral Transmucosal Drugs Product Portfolio Table 96. Eisai Co., Ltd. Recent Development Table 97. IntelGenx Corp. Company Information Table 98. IntelGenx Corp. Business Overview Table 99. IntelGenx Corp. Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. IntelGenx Corp. Oral Transmucosal Drugs Product Portfolio Table 101. IntelGenx Corp. Recent Development Table 102. LTS Lohmann Therapie-Systeme AG Company Information Table 103. LTS Lohmann Therapie-Systeme AG Business Overview Table 104. LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Product Portfolio Table 106. LTS Lohmann Therapie-Systeme AG Recent Development Table 107. NAL Pharma Company Information Table 108. NAL Pharma Business Overview Table 109. NAL Pharma Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. NAL Pharma Oral Transmucosal Drugs Product Portfolio Table 111. NAL Pharma Recent Development Table 112. Otsuka Pharmaceutical Co., Ltd. Company Information Table 113. Otsuka Pharmaceutical Co., Ltd. Business Overview Table 114. Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Product Portfolio Table 116. Otsuka Pharmaceutical Co., Ltd. Recent Development Table 117. Soligenix Company Information Table 118. Soligenix Business Overview Table 119. Soligenix Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Soligenix Oral Transmucosal Drugs Product Portfolio Table 121. Soligenix Recent Development Table 122. Viatris Company Information Table 123. Viatris Business Overview Table 124. Viatris Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Viatris Oral Transmucosal Drugs Product Portfolio Table 126. Viatris Recent Development Table 127. ZIM Laboratories Limited Company Information Table 128. ZIM Laboratories Limited Business Overview Table 129. ZIM Laboratories Limited Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. ZIM Laboratories Limited Oral Transmucosal Drugs Product Portfolio Table 131. ZIM Laboratories Limited Recent Development Table 132. GlaxoSmithKline plc Company Information Table 133. GlaxoSmithKline plc Business Overview Table 134. GlaxoSmithKline plc Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. GlaxoSmithKline plc Oral Transmucosal Drugs Product Portfolio Table 136. GlaxoSmithKline plc Recent Development Table 137. Teva Pharmaceutical Industries Ltd. Company Information Table 138. Teva Pharmaceutical Industries Ltd. Business Overview Table 139. Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Product Portfolio Table 141. Teva Pharmaceutical Industries Ltd. Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Oral Transmucosal Drugs Distributors List Table 145. Oral Transmucosal Drugs Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Oral Transmucosal Drugs Product Image Figure 2. Global Oral Transmucosal Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Transmucosal Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Transmucosal Drugs Sales (2021-2032) & (K Units) Figure 5. Global Oral Transmucosal Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral Transmucosal Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Liquid Spray Image Figure 9. Tablets Image Figure 10. Gels Image Figure 11. Films Image Figure 12. Others Image Figure 13. Global Oral Transmucosal Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Oral Transmucosal Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Oral Transmucosal Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Oral Transmucosal Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Oral Transmucosal Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Oral Transmucosal Drugs Revenue Market Share by Type (2021-2032) Figure 19. Cardiovascular Disorders Image Figure 20. Diabetes Image Figure 21. Acute Pain Managements Image Figure 22. Others Image Figure 23. Global Oral Transmucosal Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Oral Transmucosal Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Oral Transmucosal Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Oral Transmucosal Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Oral Transmucosal Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Oral Transmucosal Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 43. China Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Oral Transmucosal Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Oral Transmucosal Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Oral Transmucosal Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Oral Transmucosal Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Oral Transmucosal Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Oral Transmucosal Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Oral Transmucosal Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Oral Transmucosal Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Oral Transmucosal Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Oral Transmucosal Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid Spray
  • Tablets
  • Gels
  • Films
  • Others
Applications
  • Cardiovascular Disorders
  • Diabetes
  • Acute Pain Managements
  • Others
Companies covered
  • Access Pharmaceutical Inc.
  • Aquestive Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • C.L Pharm
  • Cure Pharmaceutical
  • Eisai Co., Ltd.
  • IntelGenx Corp.
  • LTS Lohmann Therapie-Systeme AG
  • NAL Pharma
  • Otsuka Pharmaceutical Co., Ltd.
  • Soligenix
  • Viatris
  • ZIM Laboratories Limited
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Transmucosal Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Transmucosal Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral Transmucosal Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral Transmucosal Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral Transmucosal Drugs Market Dynamics
  1. 2.1 Oral Transmucosal Drugs Industry Trends
  2. 2.2 Oral Transmucosal Drugs Industry Drivers
  3. 2.3 Oral Transmucosal Drugs Industry Opportunities and Challenges
  4. 2.4 Oral Transmucosal Drugs Industry Restraints
3 Oral Transmucosal Drugs Market by Manufacturers
  1. 3.1 Global Oral Transmucosal Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral Transmucosal Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral Transmucosal Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral Transmucosal Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Transmucosal Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral Transmucosal Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Oral Transmucosal Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Transmucosal Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Transmucosal Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Transmucosal Drugs Tier 1, Tier 2, and Tier 3
4 Oral Transmucosal Drugs Market by Type
  1. 4.1 Oral Transmucosal Drugs Type Introduction
  2. 4.1.1 Liquid Spray
  3. 4.1.2 Tablets
  4. 4.1.3 Gels
  5. 4.1.4 Films
  6. 4.1.5 Others
  7. 4.2 Global Oral Transmucosal Drugs Sales by Type
  8. 4.2.1 Global Oral Transmucosal Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Oral Transmucosal Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Oral Transmucosal Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Oral Transmucosal Drugs Revenue by Type
  12. 4.3.1 Global Oral Transmucosal Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Oral Transmucosal Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Oral Transmucosal Drugs Revenue Market Share by Type (2021-2032)
5 Oral Transmucosal Drugs Market by Application
  1. 5.1 Oral Transmucosal Drugs Application Introduction
  2. 5.1.1 Cardiovascular Disorders
  3. 5.1.2 Diabetes
  4. 5.1.3 Acute Pain Managements
  5. 5.1.4 Others
  6. 5.2 Global Oral Transmucosal Drugs Sales by Application
  7. 5.2.1 Global Oral Transmucosal Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oral Transmucosal Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Oral Transmucosal Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Oral Transmucosal Drugs Revenue by Application
  11. 5.3.1 Global Oral Transmucosal Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Oral Transmucosal Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Oral Transmucosal Drugs Revenue Market Share by Application (2021-2032)
6 Global Oral Transmucosal Drugs Sales by Region
  1. 6.1 Global Oral Transmucosal Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Transmucosal Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Transmucosal Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Oral Transmucosal Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral Transmucosal Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral Transmucosal Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral Transmucosal Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral Transmucosal Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral Transmucosal Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral Transmucosal Drugs Revenue by Region
  1. 7.1 Global Oral Transmucosal Drugs Revenue by Region
  2. 7.1.1 Global Oral Transmucosal Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral Transmucosal Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral Transmucosal Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral Transmucosal Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral Transmucosal Drugs Revenue (2021-2032)
  8. 7.2.2 North America Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral Transmucosal Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral Transmucosal Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral Transmucosal Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral Transmucosal Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Access Pharmaceutical Inc.
  2. 8.1.1 Access Pharmaceutical Inc. Company Information
  3. 8.1.2 Access Pharmaceutical Inc. Business Overview
  4. 8.1.3 Access Pharmaceutical Inc. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Access Pharmaceutical Inc. Oral Transmucosal Drugs Product Portfolio
  6. 8.1.5 Access Pharmaceutical Inc. Recent Developments
  7. 8.2 Aquestive Therapeutics, Inc.
  8. 8.2.1 Aquestive Therapeutics, Inc. Company Information
  9. 8.2.2 Aquestive Therapeutics, Inc. Business Overview
  10. 8.2.3 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Product Portfolio
  12. 8.2.5 Aquestive Therapeutics, Inc. Recent Developments
  13. 8.3 Bristol-Myers Squibb Company
  14. 8.3.1 Bristol-Myers Squibb Company Company Information
  15. 8.3.2 Bristol-Myers Squibb Company Business Overview
  16. 8.3.3 Bristol-Myers Squibb Company Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Company Oral Transmucosal Drugs Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 8.4 C.L Pharm
  20. 8.4.1 C.L Pharm Company Information
  21. 8.4.2 C.L Pharm Business Overview
  22. 8.4.3 C.L Pharm Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 C.L Pharm Oral Transmucosal Drugs Product Portfolio
  24. 8.4.5 C.L Pharm Recent Developments
  25. 8.5 Cure Pharmaceutical
  26. 8.5.1 Cure Pharmaceutical Company Information
  27. 8.5.2 Cure Pharmaceutical Business Overview
  28. 8.5.3 Cure Pharmaceutical Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cure Pharmaceutical Oral Transmucosal Drugs Product Portfolio
  30. 8.5.5 Cure Pharmaceutical Recent Developments
  31. 8.6 Eisai Co., Ltd.
  32. 8.6.1 Eisai Co., Ltd. Company Information
  33. 8.6.2 Eisai Co., Ltd. Business Overview
  34. 8.6.3 Eisai Co., Ltd. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eisai Co., Ltd. Oral Transmucosal Drugs Product Portfolio
  36. 8.6.5 Eisai Co., Ltd. Recent Developments
  37. 8.7 IntelGenx Corp.
  38. 8.7.1 IntelGenx Corp. Company Information
  39. 8.7.2 IntelGenx Corp. Business Overview
  40. 8.7.3 IntelGenx Corp. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 IntelGenx Corp. Oral Transmucosal Drugs Product Portfolio
  42. 8.7.5 IntelGenx Corp. Recent Developments
  43. 8.8 LTS Lohmann Therapie-Systeme AG
  44. 8.8.1 LTS Lohmann Therapie-Systeme AG Company Information
  45. 8.8.2 LTS Lohmann Therapie-Systeme AG Business Overview
  46. 8.8.3 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Product Portfolio
  48. 8.8.5 LTS Lohmann Therapie-Systeme AG Recent Developments
  49. 8.9 NAL Pharma
  50. 8.9.1 NAL Pharma Company Information
  51. 8.9.2 NAL Pharma Business Overview
  52. 8.9.3 NAL Pharma Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NAL Pharma Oral Transmucosal Drugs Product Portfolio
  54. 8.9.5 NAL Pharma Recent Developments
  55. 8.10 Otsuka Pharmaceutical Co., Ltd.
  56. 8.10.1 Otsuka Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Product Portfolio
  60. 8.10.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Soligenix
  62. 8.11.1 Soligenix Company Information
  63. 8.11.2 Soligenix Business Overview
  64. 8.11.3 Soligenix Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Soligenix Oral Transmucosal Drugs Product Portfolio
  66. 8.11.5 Soligenix Recent Developments
  67. 8.12 Viatris
  68. 8.12.1 Viatris Company Information
  69. 8.12.2 Viatris Business Overview
  70. 8.12.3 Viatris Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Viatris Oral Transmucosal Drugs Product Portfolio
  72. 8.12.5 Viatris Recent Developments
  73. 8.13 ZIM Laboratories Limited
  74. 8.13.1 ZIM Laboratories Limited Company Information
  75. 8.13.2 ZIM Laboratories Limited Business Overview
  76. 8.13.3 ZIM Laboratories Limited Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 ZIM Laboratories Limited Oral Transmucosal Drugs Product Portfolio
  78. 8.13.5 ZIM Laboratories Limited Recent Developments
  79. 8.14 GlaxoSmithKline plc
  80. 8.14.1 GlaxoSmithKline plc Company Information
  81. 8.14.2 GlaxoSmithKline plc Business Overview
  82. 8.14.3 GlaxoSmithKline plc Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GlaxoSmithKline plc Oral Transmucosal Drugs Product Portfolio
  84. 8.14.5 GlaxoSmithKline plc Recent Developments
  85. 8.15 Teva Pharmaceutical Industries Ltd.
  86. 8.15.1 Teva Pharmaceutical Industries Ltd. Company Information
  87. 8.15.2 Teva Pharmaceutical Industries Ltd. Business Overview
  88. 8.15.3 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Product Portfolio
  90. 8.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Transmucosal Drugs Value Chain Analysis
  2. 9.1.1 Oral Transmucosal Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Transmucosal Drugs Production Mode & Process
  6. 9.2 Oral Transmucosal Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Transmucosal Drugs Distributors
  9. 9.2.3 Oral Transmucosal Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst